INmune Bio, Inc. (INMB)

INmune Bio's stock price has experienced significant volatility, losing approximately 78.7% over the past 12 months, with a market capitalization of $39.3 million as of May 6, 2026. Key events include Q1 2026 financial results showing a narrower-than-expected loss per share, strategic expansion of its CORDStrom™ MSC Platform collaboration with Anthony Nolan, deepening its CORDStrom supply pact with Anthony Nolan, news about an expanded equity plan and board elections for the company's 2026 meeting, announcement of its 2025 results and a business update including a "pipeline reset" following gains in the CORDStrom™ program and a "setback" for XPro™, outlining its RDEB and Alzheimer's trial paths, and mapping the XPro1595 registrational path in an Alzheimer's webinar.

As a clinical-stage biotechnology company, INmune Bio, Inc. is primarily focused on research, development, and clinical trials of its product candidates. Its products are not yet commercialized, and therefore, traditional demand seasonality does not apply. Demand for its investigational therapies is driven by the progression of clinical trials, regulatory milestones, and the medical need for treatments in the disease areas it targets.

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system for diseases driven by chronic inflammation, cancer, and neurological disorders. The company modulates innate immune dysfunction through three primary product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform (XPro™) which selectively neutralizes soluble tumor necrosis factor (sTNF) and is in clinical development for neurological diseases, cancer, COVID-19 complications, and NASH; the CORDStrom™ platform, a cell medicine platform consisting of allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) aimed at treating complex inflammatory, degenerative, and autoimmune diseases; and the INKmune® platform, designed to prime a patient's natural killer (NK) cells to eliminate minimal residual disease in cancer patients.

INmune Bio, Inc. is incorporated in Nevada with principal executive offices in Boca Raton, Florida. Its clinical development and regulatory activities have a global reach, with planned MAA submissions for CORDStrom™ in the UK and EU, and a BLA submission targeted for the US. The company also received an Australian R&D rebate in January 2026.

INmune Bio's brand reputation has been influenced by clinical progress and financial challenges. Positive developments, such as the advancement of the CORDStrom™ platform towards regulatory filings and FDA alignment for an adaptive Phase 2b/3 pathway for XPro™ in early Alzheimer's disease, contribute positively. However, the "going concern" warning due to a limited cash runway and the "setback" of the XPro™ Alzheimer's candidate have negatively impacted its financial reputation and investor confidence.

INmune Bio, Inc. has a diverse ownership structure. As of May 7, 2026, there are 81 institutional owners holding a total of 5,100,274 shares, representing approximately 19.12% of the shares outstanding. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and Geode Capital Management, Llc. Individual insiders hold a significant portion of the company's stock, representing about 27.51% of total shares outstanding as of February 15, 2026, including TenPercentOwner Inc Xencor, President and CEO Raymond Joseph Tesi, and Chief Scientific Officer Mark William Lowdell.